---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-003502"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:48:46.334099+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences names Takeda veteran Adam Zaeske as CCO; Dierks steps down

## Summary
- Jeffrey Dierks steps down as CCO effective March 31, 2025; receives $476,215 cash and accelerated vesting for 2025 awards.
- Adam Zaeske appointed as EVP and CCO effective March 31, 2025; previously Head of Central, South, and Eastern Europe at Takeda.
- Zaeske managed a $2B business across 25 countries with 900 employees; delivered 3 consecutive years of double-digit growth.
- Company reaffirms 2025 revenue guidance and states WAKIX is a $1B+ opportunity in adult narcolepsy alone.
- Zaeske brings 25 years of pharma experience, including rare disease and neurology launches.

## SEC filing metadata
- accession: 0001558370-25-003502
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837025003502/0001558370-25-003502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837025003502/hrmy-20250320x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-003502
- JSON: https://secwatch.observer/filing/0001558370-25-003502.json
- Plain text: https://secwatch.observer/filing/0001558370-25-003502.txt

## Key facts
- Executive change
  Jeffrey Dierks departed as Chief Commercial Officer at Harmony Biosciences Holdings, Inc..
  - Action: departing
  - Role: Chief Commercial Officer
  source text: Jeffrey Dierks will be departing from the Company as its Chief Commercial Officer, effective as of March 31, 2025 (the “Effective Date”), for personal reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837025003502/0001558370-25-003502-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.